Search Results
May 06, 2026, 06:51 ET Timken Reports First-Quarter 2026 Results
reorganization charges (including items recorded in cost of products sold) relate to: (i) plant closures; (ii) the rationalization of certain plants; (iii) severance related to cost reduction initiatives; (iv) impairment of assets; and (v) related depreciation and amortization. The Company re-assesses its
More news about: The Timken Company
May 06, 2026, 06:34 ET Kaneka Ubiquinol™ Wins Coveted Vitafoods Europe Innovation Award 2026 in Partnership with Eqology
protection.With mitochondria generating approximately 90% of the body's energy[ii] and natural ubiquinol levels declining from age 20+[iii], supporting mitochondrial energy production is increasingly recognised as important for cardiovascular health, reproductive health, women's health,
More news about: Kaneka Ubiquinol™
May 06, 2026, 06:30 ET Restaurant Brands International Inc. Reports First Quarter 2026 Results
pressures and currency fluctuations on our and our franchisees' results of operations and business; (ii) our remodel program and refranchising efforts; (iii) future share repurchases; (iv) leverage and free cash flow, including our path to achieving investment-grade status; (v) our and our franchisees' future
More news about: Restaurant Brands International Inc.
May 06, 2026, 06:30 ET Restaurant Brands International Inc. Reports First Quarter 2026 Results
pressures and currency fluctuations on our and our franchisees' results of operations and business; (ii) our remodel program and refranchising efforts; (iii) future share repurchases; (iv) leverage and free cash flow, including our path to achieving investment-grade status; (v) our and our franchisees' future
More news about: Restaurant Brands International Inc.
May 06, 2026, 06:30 ET Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations
TABLE IIIPERRIGO COMPANY PLC
More news about: Perrigo Company plc
May 06, 2026, 06:27 ET Elanco Animal Health Reports First Quarter 2026 Results
divestiture or amortization of intangible assets, that some may consider important in evaluating our performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future and (iv) they may not exclude all unusual or non-recurring
More news about: Elanco Animal Health
May 06, 2026, 06:00 ET Hyperscale Data to Expand Digital and Physical Asset Treasury with Planned Purchase of 2,000 Ounces of Gold
centered on long-term asset strength, balance sheet resilience and exposure to assets we believe will remain important over time," said Milton "Todd" Ault III, Executive Chairman of Hyperscale Data. "We currently hold approximately 681 Bitcoin and 10,000 ounces of silver, and we intend to purchase
More news about: Hyperscale Data Inc.
May 06, 2026, 02:52 ET Bitmine Immersion Technologies (BMNR) 宣佈其以太幣 (ETH) 持有量達 518 萬枚，加密資產及現金總持有額達 131 億美元
Bitmine 為美國第 173 大最活躍交易股票，日均成交額達 6.25 億美元（5 日平均）Bitmine 持續獲得頂級機構投資者支持，包括 ARK 的 Cathie Wood、MOZAYYX、Founders Fund、Bill Miller III、Pantera、Kraken、DCG、Galaxy Digital 以及個人投資者 Thomas "Tom" Lee，攜手支持 Bitmine 收購 5% 以太幣的目標康州諾沃克2026年5月6日
More news about: Bitmine Immersion Technologies, Inc.
May 06, 2026, 00:21 ET Bitmine Immersion Technologies (BMNR) annuncia che le partecipazioni in ETH raggiungono i 5,18 milioni di token e che le partecipazioni totali in criptovalute e contanti ammontano a 13,1 miliardi di dollari
continua a essere sostenuta da un gruppo di investitori istituzionali di prim'ordine tra cui Cathie Wood di ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital e l'investitore privato Thomas "Tom" Lee a sostegno dell'obiettivo di Bitmine di acquisire il 5% di ETH
More news about: Bitmine Immersion Technologies, Inc.
May 06, 2026, 00:15 ET Bitmine Immersion Technologies (BMNR) anuncia que sus tenencias de ETH alcanzan los 5,18 millones de tokens y sus tenencias totales en criptomonedas y efectivo ascienden a 13.100 millones de dólares
con el apoyo de un grupo selecto de inversionistas institucionales, entre los que se incluyen Cathie Wood de ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital y el inversionista particular Thomas "Tom" Lee, para respaldar el objetivo de Bitmine de adquirir el 5 % de ETH
More news about: Bitmine Immersion Technologies, Inc.
May 06, 2026, 00:11 ET BitMine Immersion Technologies (BMNR) anuncia que suas participações em ETH somam 5,18 milhões de tokens e que o total em criptomoedas e caixa é de US$ 13,1 bilhões
BitMine continua apoiada por um grupo de investidores institucionais de destaque, incluindo Cathie Wood da ARK, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital e o investidor pessoal Thomas "Tom" Lee, para apoiar a meta da BitMine de adquirir 5% do ETHNORWALK,
More news about: Bitmine Immersion Technologies, Inc.
May 06, 2026, 00:00 ET Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
only 40.1% [4].Data from the Completed AP301 China Pivotal Phase III Clinical TrialAP301 demonstrated robust and clinically meaningful efficacy in the completed China pivotal Phase III clinical trial (RESPOND-1, Study AP301-HP-02) [5]. The study was led by Professor
More news about: Alebund Pharmaceuticals
May 05, 2026, 20:00 ET Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
(denileukin diftitox-cxdl), approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, and has also entered into a definitive agreement for the immediate exercise
More news about: Citius Oncology, Inc.
May 05, 2026, 17:09 ET CWH CLASS ACTION REMINDER - Get in Touch with Robbins LLP to Discuss Your Rights Against Camping World Holdings, Inc.
optimize profit using "data analytics;" (ii) the Company overstated the retail demand of consumers it was experiencing and/or reasonably expected; (iii) as a result, the Company would require "strict, corrective inventory management objectives," negatively impacting gross profit and margins; and (iv)
More news about: Robbins LLP
May 05, 2026, 17:01 ET Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
population.1,6,7Marketing authorisations for PEDMARQSI® were based on safety and efficacy data from two open label, randomised Phase III trials: SIOPEL 6 and COG ACCL0431.2,3For more information on PEDMARQSI® find the CMI here:
More news about: Norgine
May 05, 2026, 17:01 ET Norgine begrüßt die TGA-Zulassung von PEDMARQSI® (Natriumthiosulfat wasserfrei) in Australien zur Vorbeugung von Cisplatin-induziertem Hörverlust bei Kindern1
Genehmigung für das Inverkehrbringen von PEDMARQSI® basierte auf Sicherheits- und Wirksamkeitsdaten aus zwei offenen, randomisierten Phase-III-Studien: SIOPEL 6 und COG ACCL0431.2,3Weitere Informationen zu PEDMARQSI® finden Sie auf der CMI hier:
More news about: Norgine
May 05, 2026, 17:01 ET Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
population.1,6,7Marketing authorisations for PEDMARQSI® were based on safety and efficacy data from two open label, randomised Phase III trials: SIOPEL 6 and COG ACCL0431.2,3For more information on PEDMARQSI® find the CMI here:
More news about: Norgine
May 05, 2026, 17:01 ET Norgine celebra el registro de la TGA en Australia de PEDMARQSI®
pacientes.1,6,7Las autorizaciones de comercialización de PEDMARQSI® se basaron en datos de seguridad y eficacia de dos ensayos de fase III aleatorizados y abiertos: SIOPEL 6 y COG ACCL0431.2,3Para obtener más información sobre PEDMARQSI®, consulte la información para el
More news about: Norgine
May 05, 2026, 17:01 ET Norgine se félicite de l'enregistrement par la TGA en Australie de PEDMARQSI® (thiosulfate de sodium anhydre) pour la prévention de la perte auditive induite par le cisplatine chez les enfants1
patients.1,6,7Les autorisations de mise sur le marché du PEDMARQSI® ont été fondées sur les données de sécurité et d'efficacité de deux essais de phase III ouverts et randomisés : SIOPEL 6 et COG ACCL0431.2,3Pour plus d'informations sur PEDMARQSI® , vous trouverez le CMI ici :
More news about: Norgine
May 05, 2026, 16:58 ET The Chemours Company Reports First Quarter Results
Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes
More news about: The Chemours Company
May 05, 2026, 16:55 ET Robbins LLP Urges RGC Investors Who Lost Money Investing in Regencell Bioscience Holdings Limited to Contact the Firm for Information About Leading the Securities Class Action
manipulation; (ii) the resulting volatility in the market for the Company's ordinary shares exposed Regencell's investors to significant financial risk; (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant
More news about: Robbins LLP
May 05, 2026, 16:30 ET Corteva Delivers Strong 1Q 2026, Reaffirms 2026 Outlook, On-Track for 4Q 2026 Separation
the necessary regulatory approvals for some of the company's products; (ii) failure to successfully develop and commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products;
More news about: Corteva Agriscience
May 05, 2026, 16:15 ET Talos Energy Announces First Quarter 2026 Operational and Financial Results
supplemental indicators of the operational performance of our business, (ii) additional criteria for evaluating our performance relative to our peers and (iii) supplemental information to investors about certain material non-cash and/or other items that may not continue at the same level in the future. Adjusted
More news about: Talos Energy
May 05, 2026, 16:15 ET EOG Resources Reports First Quarter 2026 Results
general, EOG excludes impairments which are (i) attributable to declines in commodity prices, (ii) related to sales of certain oil and gas properties or (iii) the result of certain other events or decisions (e.g., a periodic review of EOG's oil and gas properties or other assets). EOG believes excluding these
More news about: EOG Resources, Inc.
May 05, 2026, 16:15 ET Chord Energy Reports First Quarter 2026 Financial and Operating Results, Updates 2026 Outlook and Declares Base Dividend
Earnings Per Share is calculated as (i) Adjusted Net Income (ii) less distributed and undistributed earnings allocated to participating securities (iii) divided by the weighted average number of diluted shares outstanding for the periods presented.The following table presents reconciliations of
More news about: Chord Energy